Multiple Myeloma Patients in Middle East Diagnosed Younger Than Global Average
A targeted literature review of multiple myeloma across the Middle East and North Africa shows that patients are diagnosed at ...
A targeted literature review of multiple myeloma across the Middle East and North Africa shows that patients are diagnosed at ...
A detailed case report shows how bone marrow analysis and genetic testing can distinguish rare immunoglobulin M multiple myeloma from ...
A comprehensive scientific synthesis reveals how dipeptides and tripeptides function as metabolic nutrients, intracellular signaling effectors, and therapeutic building blocks ...
A 66-year-old female patient presenting with a three-month history of isolated epigastric pain achieved a profound hematologic response following targeted ...
A study in Genome Medicine reveals that microsatellite-stable colorectal cancer with low chromosomal instability responds to anti-PD-1 immunotherapy and is ...
A multifunctional molecularly imprinted nanocarrier combines magnetic recovery, dual-channel fluorescence tracking, and pH-responsive zero-order release of the anticancer drug bortezomib.
A study of 180 patients with AL amyloidosis finds that daratumumab induction therapy and chemo-free mobilization reduce CD34-positive stem cell ...
Targeting the chemokine receptor CCR5 with maraviroc suppresses M2 macrophage polarization and restores bortezomib sensitivity in multiple myeloma models.
Clinicians achieved sustained remission using salvage multi-agent chemotherapy in a patient with Sjögren's disease complicated by severe TAFRO syndrome.
A retrospective pilot study in BMC Veterinary Research reports that bortezomib demonstrated therapeutic activity in five cats with plasma cell-derived ...
Researchers found that the chemotherapy drug bortezomib triggers concentration-dependent intracerebral hemorrhage and lipid metabolism disruption in developing zebrafish larvae.
Combining bortezomib and riluzole synergistically inhibited cell growth, migration, and stemness markers in laboratory models of human castration-resistant prostate cancer.
Researchers identified IGFBP5 as a negative regulator of adhesion-mediated bortezomib resistance in multiple myeloma that modulates FAK/Src signaling.
A new review shows that early T-cell precursor acute lymphoblastic leukemia, once considered uniformly high risk, now demands genomic subtyping ...
An interim analysis of the BORTEM-17 phase IB/II trial found that sequential bortezomib and temozolomide achieved disease control in four ...
A 37-year-old man walked into a hospital in China with black, tarry stools and blood pressure so high it threatened ...
Researchers found that the gap junction protein Cx26 relocates to mitochondria in metastatic colorectal cancer, driving EMT and calcium signaling, ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.